complement therapeutics
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Phil Taylor
C3 glomerulopathy, complement therapeutics, iptacopan, nephrology, Novartis, rare disease
0 Comment
Apellis reports mixed data with eye drug, but plans to file anyway
Phil Taylor
Apellis Pharma, blindness, complement therapeutics, Empaveli, geographic atrophy, ophthalmology
0 Comment
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial
Phil Taylor
Alexion, amyotrophic lateral sclerosis, AstraZeneca, complement therapeutics, neurodegenerative disease, Soliris, UCB, Ultomiris, zilucoplan
0 Comment
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Phil Taylor
Alexion, complement therapeutics, EHA 2021, Haematology, iptacopan, Novartis, rare disease, Soliris, Ultomiris
0 Comment
3rd Annual Complement-based Drug Development Summit 2019
ilektra.stouka@hansonwade.com
clinical approval, clinical landscape, clinical trial, complement therapeutics
0 Comment
November 13-15, 2019 | Boston, MA